Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
Fluoxetine Improves Visual Acuity in Adult Amblyopia
A groundbreaking study conducted by researchers from the Eye Research Center, Farabi Eye Hospital, and Tehran University of Medical Sciences has revealed that fluoxetine, a commonly used antidepressant, significantly improves visual acuity (VA) in adults with amblyopia. The study, led…
Stem Cell Breakthrough Restores Vision in LSCD Patients
In a groundbreaking achievement, researchers from Osaka University in Japan have successfully conducted the first human trial using induced pluripotent stem-cell-derived corneal epithelium to treat limbal stem cell deficiency (LSCD). This innovative approach marks a significant advancement in vision restoration…
Bimekizumab Reduces Uveitis Incidence in axSpA Patients
The study led by Matthew A. Brown, Genomics England, London, United Kingdom, and Martin Rudwaleit, Klinikum Bielefeld, University of Bielefeld, Bielefeld, Germany. Patients with axial spondyloarthritis (axSpA) treated with bimekizumab exhibited a markedly lower incidence of uveitis compared to those receiving…
ANX007 Protects Vision in Dry AMD – AAO 2024
A new investigational drug, ANX007, offers hope for the millions of people suffering from geographic atrophy, a severe form of dry age-related macular degeneration (AMD). The drug’s potential to reduce vision loss and protect essential retinal structures was highlighted at…
SLT Beats Medications in Glaucoma – AAO 2024
A recent retrospective analysis of the Laser in Glaucoma and Ocular Hypertension (LiGHT) trial data demonstrated that selective laser trabeculoplasty (SLT) as a first-line treatment significantly outperforms glaucoma medications in reducing the rate of visual field (VF) loss. This study,…
Study: Aromatherapy Eases Post-Surgery Anxiety and Pain
A recent study suggests that aromatherapy may effectively reduce postoperative anxiety and pain in patients undergoing oculoplastic procedures under monitored anesthetic sedation. Published in Ophthalmic Plastic and Reconstructive Surgery, this randomized controlled trial highlights the potential of aromatherapy as an…
De-escalated Chemo Effective for High-Risk Retinoblastoma
A recent study reveals that a shortened adjuvant chemotherapy regimen offers similar efficacy and improved safety for infants with unilateral pathologic high-risk retinoblastoma. Results showed enhanced five-year disease-free survival (DFS) among infants receiving three cycles of chemotherapy compared to those…
Cambium Bio Raises Funds for Dry Eye Trials
Cambium Bio Limited, a clinical-stage regenerative medicine company, announced that it has successfully completed an A$3.0 million capital raising round. This funding will primarily support the development of Elate Ocular, a novel treatment for dry eye disease (DED), through registration-enabling…
Galimedix Starts Phase 1 Trial for Oral GAL-101
Galimedix Therapeutics Inc. has announced the initiation of dosing in a Phase 1 clinical trial for oral GAL-101, an innovative amyloid beta (Aβ) aggregation modulator. The study aims to assess the therapy’s safety, tolerability, and pharmacokinetics, marking a significant step…
Ocular Therapeutix Progresses Phase 3 OTX-TKI Trial
Ocular Therapeutix has announced that over 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). This marks a critical milestone in the development of the first registrational trial for OTX-TKI as a…